Supplementing appears to be safe in the short-term, but more research is needed on its long-term effects
Two oral GLP-1s on the US market within three months of each other, a European recommendation in May, and a pipeline of competitors moving fast behind them
It does not compete directly on maximum weight loss with injectable multi-receptor agonists but instead offers a differentiated value proposition based on oral convenience, no restrictions, lower manufacturing costs, and the potential to dramatically expand the addressable patient population for GLP-1 therapy
Whichever you are researching, remember the framing behind the melanotan 1 vs 2 question: both are research compounds, neither is an approved cosmetic, and product quality on the unregulated market is unpredictable
Hexadecandionyl was attached to desB30 human insulin via a L--glutamic acid spacer